Complement Is an Essential Component of the Immune Response to Adeno-Associated Virus Vectors
Open accessThe DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV) vectors are associated with relatively mild host immune responses in vivo. Although AAV induces very weak innate immune responses, neutralizing antibodies against the vector capsid and transgene still occur. To understand further the basis of the antiviral immune response to AAV vectors, studies were performed to characterize AAV interactions with macrophages. Primary mouse macrophages and human THP-1 cells transduced in vitro using an AAV serotype 2 (AAV2) vector encoding green fluorescent protein did not result in measurable transgene expression. An assessment of internalized vector genomes showed that AAV2 vector uptake was enhanced in the presence of normal but not heat-inactivated or C3-depleted mouse/human serum. Enhanced uptake in the presence of serum coincided with increased macrophage activation as determined by the expression of NF-κB-dependent genes such as macrophage inflammatory protein 2 (MIP-2), interleukin-1β (IL-1β), IL-8, and MIP-1β. AAV vector serotypes 1 and 8 also activated human and mouse macrophages in a serum-dependent manner. Immunoprecipitation studies demonstrated the binding of iC3b complement protein to the AAV2 capsid in human serum. AAV2 did not activate the alternative pathway of the complement cascade and lacked cofactor activity for factor I-mediated degradation of C3b to iC3b. Instead, our results suggest that the AAV capsid also binds complement regulatory protein factor H. In vivo, complement receptor 1/2- and C3-deficient mice displayed impaired humoral immunity against AAV2 vectors, with a delay in antibody development and significantly lower neutralizing antibody titers. These results show that the complement system is an essential component of the host immune response to AAV.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Complement activation in response to systemic AAV administration and related acute toxicities has been reported for numerous clinical and preclinical studies (39, 52–56).”
From Intravitreal AAV vector delivery induces integrin-dependent ocular inflammation, complement activation, and antiviral and DNA damage responses (2026) · cites this paper as [53]
In the citing paper
“One study suggested that AAV capsid interacts with C3, resulting in a higher AAV2 uptake in macrophages and a subsequent upregulation of cytokines, such as IL-8, IL-1β, and macrophage inflammatory protein [52].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [52]
In the citing paper
“have been shown to delay the humoral immune response and significantly lower titers of neutralizing antibodies in response to AAV in mice (24).”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [24]
In the citing paper
“In vitro, AAV activated complement through the classical antibody-mediated pathway, while complement receptors were involved in anti-AAV antibody formation in mice (24).”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [24]
In the citing paper
“Complement components have been also shown to bind directly AAV capsid, increasing cytokine/chemokine gene expression and vector uptake in monocytic cell lines or primary murine bone marrow macrophages.”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [24]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Establishment and characterization of a human acute monocytic leukemia cell line (THP‐1)
Tsuchiya, S., Yamabe, M., Yamaguchi, Y., Kobayashi, Y., Konno, T., & Tada, K. (1980) · International Journal of Cancer · doi:10.1002/ijc.2910260208 · Cited by 2,254
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
The complement system in regulation of adaptive immunity
Carroll, M. C. (2004) · Nature Immunology · doi:10.1038/ni1113 · Cited by 1,035 · cited 1×
“Recent research has shown that complement can also modulate T-cell responses, both through direct modulation of the T cell and indirectly through antigen-presenting cells (5, 33).”
BackgroundCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Immune responses to adenovirus and adeno-associated virus in humans
Chirmule, N., Propert, K. J., Magosin, S. A., Qian, Y., Qian, R., & Wilson, J. M. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300994 · Cited by 684 · cited 1×
“The prevalence of serum antibodies against AAV in the population is between 35 and 80%, according to age group and geographical location (8, 17, 52).”
BackgroundCRIg: A Macrophage Complement Receptor Required for Phagocytosis of Circulating Pathogens
Helmy, K. Y., Katschke, K. J., Gorgani, N. N., Kljavin, N. M., Elliott, J. M., Diehl, L., Scales, S. J., Ghilardi, N., & van Lookeren Campagne, M. (2006) · Cell · doi:10.1016/j.cell.2005.12.039 · Cited by 628
Kessler, P. D., Podsakoff, G. M., Chen, X., McQuiston, S. A., Colosi, P. C., Matelis, L. A., Kurtzman, G. J., & Byrne, B. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14082 · Cited by 614
Schwende, H., Fitzke, E., Ambs, P., & Dieter, P. (1996) · Journal of Leukocyte Biology · doi:10.1002/jlb.59.4.555 · Cited by 581
Chapter 8 Use of Recombinant Adenovirus for Metabolic Engineering of Mammalian Cells
Becker, T. C., Noel, R. J., Coats, W. S., Gómez-Foix, A. M., Alam, T., Gerard, R. D., & Newgard, C. B. (1994) · Methods in Cell Biology · doi:10.1016/s0091-679x(08)60603-2 · Cited by 569
Herzog, R. W., Yang, E. Y., Couto, L. B., Hagstrom, J. N., Elwell, D., Fields, P. A., Burton, M., Bellinger, D. A., Read, M. S., Brinkhous, K. M., et al. (1999) · Nature Medicine · doi:10.1038/4743 · Cited by 554
Sahu, A., & Lambris, J. D. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1800103.x · Cited by 525
The role of complement in inflammation and phagocytosis
Frank, M. M., & Fries, L. F. (1991) · Immunology Today · doi:10.1016/0167-5699(91)90009-i · Cited by 503
Jooss, K., Yang, Y., Fisher, K. J., & Wilson, J. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.4212-4223.1998 · Cited by 470 · cited 1×
“Impaired transduction by AAV vectors has also been reported to occur in dendritic cells and in hematopoietic progenitor cells, due to a failure of the virus to efficiently perform second-strand DNA synthesis (26, 32, 57, 75).”
BackgroundMarkedly impaired humoral immune response in mice deficient in complement receptors 1 and 2.
Molina, H., Holers, V. M., Li, B., Fung, Y., Mariathasan, S., Goellner, J., Strauss-Schoenberger, J., Karr, R. W., & Chaplin, D. D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3357 · Cited by 465
Self-citationHorstmann, R. D., Sievertsen, H. J., Knobloch, J., & Fischetti, V. A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.5.1657 · Cited by 451
Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity
Shayakhmetov, D. M., Gaggar, A., Ni, S., Li, Z.-Y., & Lieber, A. (2005) · Journal of Virology · doi:10.1128/jvi.79.12.7478-7491.2005 · Cited by 427
Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors
Zaiss, A.-K., Liu, Q., Bowen, G. P., Wong, N. C. W., Bartlett, J. S., & Muruve, D. A. (2002) · Journal of Virology · doi:10.1128/jvi.76.9.4580-4590.2002 · Cited by 394
Self-citationUpdate on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV)
Erles, K., Seb�kov�, P., & Schlehofer, J. R. (1999) · Journal of Medical Virology · doi:10.1002/(sici)1096-9071(199911)59:3<406::aid-jmv22>3.0.co;2-n · Cited by 342
T-cell regulation: with complements from innate immunity
Kemper, C., & Atkinson, J. P. (2007) · Nature Reviews Immunology · doi:10.1038/nri1994 · Cited by 340
Macrophage complement receptors and pathogen clearance
van Lookeren Campagne, M., Wiesmann, C., & Brown, E. J. (2007) · Cellular Microbiology · doi:10.1111/j.1462-5822.2007.00981.x · Cited by 332
CR3: a general purpose adhesion-recognition receptor essential for innate immunity
Ehlers, M. R. W. (2000) · Microbes and Infection · doi:10.1016/s1286-4579(00)00299-9 · Cited by 323
Inhibition of the Complement Cascade by the Major Secretory Protein of Vaccinia Virus
Kotwal, G. J., Isaacs, S. N., McKenzie, R., Frank, M. M., & Moss, B. (1990) · Science · doi:10.1126/science.2237434 · Cited by 321
Fang, Y., Xu, C., Fu, Y.-X., Holers, V. M., & Molina, H. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.11.5273 · Cited by 320
Self-citationKopf, M., Abel, B., Gallimore, A., Carroll, M., & Bachmann, M. F. (2002) · Nature Medicine · doi:10.1038/nm0402-373 · Cited by 311
Matsumoto, A. K., Kopicky-Burd, J., Carter, R. H., Tuveson, D. A., Tedder, T. F., & Fearon, D. T. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.1.55 · Cited by 305
Clark, K. R., Liu, X., Mcgrath, J. P., & Johnson, P. R. (1999) · Human Gene Therapy · doi:10.1089/10430349950018427 · Cited by 305
Dependence of Germinal Center B Cells on Expression of CD21/CD35 for Survival
Fischer, M. B., Goerg, S., Shen, L., Prodeus, A. P., Goodnow, C. C., Kelsoe, G., & Carroll, M. C. (1998) · Science · doi:10.1126/science.280.5363.582 · Cited by 282
Ram, S., McQuillen, D. P., Gulati, S., Elkins, C., Pangburn, M. K., & Rice, P. A. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.4.671 · Cited by 278
Structure–function relationships of complement receptor type 1
Krych‐Goldberg, M., & Atkinson, J. P. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1800110.x · Cited by 257
Moskalenko, M., Chen, L., van Roey, M., Donahue, B. A., Snyder, R. O., McArthur, J. G., & Patel, S. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.4.1761-1766.2000 · Cited by 253
Chung, K. M., Liszewski, M. K., Nybakken, G., Davis, A. E., Townsend, R. R., Fremont, D. H., Atkinson, J. P., & Diamond, M. S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605668103 · Cited by 238
Functional Significance of Factor H Binding to Neisseria meningitidis
Schneider, M. C., Exley, R. M., Chan, H., Feavers, I., Kang, Y.-H., Sim, R. B., & Tang, C. M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.12.7566 · Cited by 230
Sustained correction of bleeding disorder in hemophilia B mice by gene therapy
Wang, L., Takabe, K., Bidlingmaier, S. M., Ill, C. R., & Verma, I. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3906 · Cited by 222
Peden, C. S., Burger, C., Muzyczka, N., & Mandel, R. J. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6344-6359.2004 · Cited by 222 · cited 1×
“However, AAV vectors can induce cellular and humoral responses to the transgene product (15, 21, 22, 41, 43, 49, 71) and AAV-mediated gene therapy leads to the development of antibodies against the vector capsid, confirming that a significant interaction with the immune system exists (9, 28, 55).”
BackgroundAn Oral Vaccine Against NMDAR1 with Efficacy in Experimental Stroke and Epilepsy
During, M. J., Symes, C. W., Lawlor, P. A., Lin, J., Dunning, J., Fitzsimons, H. L., Poulsen, D., Leone, P., Xu, R., Dicker, B. L., et al. (2000) · Science · doi:10.1126/science.287.5457.1453 · Cited by 220
Regulation of the Adhesion versus Cytotoxic Functions of the Mac-1/CR3/αMβ2 - lntegrin Glycoprotein
Ross, G. D. (2000) · Critical Reviews™ in Immunology · doi:10.1615/critrevimmunol.v20.i3.20 · Cited by 217
Immune Responses to Adeno-Associated Virus Vectors
Zaiss, A., & Muruve, D. (2005) · Current Gene Therapy · doi:10.2174/1566523054065039 · Cited by 213
Self-citationChirmule, N., Xiao, W., Truneh, A., Schnell, M. A., Hughes, J. V., Zoltick, P., & Wilson, J. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.5.2420-2425.2000 · Cited by 198 · cited 2×
“AAV vectors induce a mild innate immune response and a prominent adaptive response in the form of neutralizing antibodies to the virus capsid (9, 52, 73).”
BackgroundTNFα and MIP-2: role in particle-induced inflammation and regulation by oxidative stress
Driscoll, K. E. (2000) · Toxicology Letters · doi:10.1016/s0378-4274(99)00282-9 · Cited by 189
The complement system in B cell regulation
CARROLL, M. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.03.017 · Cited by 177
McNearney, T. A., Odell, C., Holers, V. M., Spear, P. G., & Atkinson, J. P. (1987) · The Journal of experimental medicine · doi:10.1084/jem.166.5.1525 · Cited by 169
Self-citationHernandez, Y. J., Wang, J., Kearns, W. G., Loiler, S., Poirier, A., & Flotte, T. R. (1999) · Journal of Virology · doi:10.1128/jvi.73.10.8549-8558.1999 · Cited by 169
Pangburn, M. K. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)80300-8 · Cited by 166
Regulation of Complement Activity by Vaccinia Virus Complement-Control Protein
McKenzie, R., Kotwal, G. J., Moss, B., Hammer, C. H., & Frank, M. M. (1992) · Journal of Infectious Diseases · doi:10.1093/infdis/166.6.1245 · Cited by 164
Mehlhop, E., Whitby, K., Oliphant, T., Marri, A., Engle, M., & Diamond, M. S. (2005) · Journal of Virology · doi:10.1128/jvi.79.12.7466-7477.2005 · Cited by 155
Role of the YadA protein in prevention of opsonization of Yersinia enterocolitica by C3b molecules
China, B., Sory, M. P., N'Guyen, B. T., De Bruyere, M., & Cornelis, G. R. (1993) · Infection and Immunity · doi:10.1128/iai.61.8.3129-3136.1993 · Cited by 154
Human complement regulators: a major target for pathogenic microorganisms
Lindahl, G., Sjöbring, U., & Johnsson, E. (2000) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)00049-7 · Cited by 154
Favre, D., Blouin, V., Provost, N., Spisek, R., Porrot, F., Bohl, D., Marmé, F., Chérel, Y., Salvetti, A., Hurtrel, B., et al. (2002) · Journal of Virology · doi:10.1128/jvi.76.22.11605-11611.2002 · Cited by 150
Hansen, J., Qing, K., Kwon, H.-J., Mah, C., & Srivastava, A. (2000) · Journal of Virology · doi:10.1128/jvi.74.2.992-996.2000 · Cited by 147
Sahu, A., Isaacs, S. N., Soulika, A. M., & Lambris, J. D. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.11.5596 · Cited by 146
Liu, D.-W., Tsao, Y.-P., Kung, J. T., Ding, Y.-A., Sytwu, H.-K., Xiao, X., & Chen, S.-L. (2000) · Journal of Virology · doi:10.1128/jvi.74.6.2888-2894.2000 · Cited by 146
Yuasa, K., Sakamoto, M., Miyagoe‐Suzuki, Y., Tanouchi, A., Yamamoto, H., Li, J., Chamberlain, J. S., Xiao, X., & Takeda, S. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301829 · Cited by 138
Virus complement evasion strategies
Favoreel, H. W., Van de Walle, G. R., Nauwynck, H. J., & Pensaert, M. B. (2003) · Journal of General Virology · doi:10.1099/vir.0.18709-0 · Cited by 137
Fields, P. A., Kowalczyk, D. W., Arruda, V. R., Armstrong, E., McCleland, M. L., Hagstrom, J. N., Pasi, K. J., Ertl, H. C. J., Herzog, R. W., & High, K. A. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0032 · Cited by 129
Qing, K., Hansen, J., Weigel-Kelley, K. A., Tan, M., Zhou, S., & Srivastava, A. (2001) · Journal of Virology · doi:10.1128/jvi.75.19.8968-8976.2001 · Cited by 126 · cited 1×
“Impaired transduction by AAV vectors has also been reported to occur in dendritic cells and in hematopoietic progenitor cells, due to a failure of the virus to efficiently perform second-strand DNA synthesis (26, 32, 57, 75).”
BackgroundComplement activation by recombinant adenoviruses
Cichon, G., Boeckh-Herwig, S., Schmidt, H., Wehnes, E., Müller, T., Pring-Akerblom, P., & Burger, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301611 · Cited by 123
Manning, W. C., Paliard, X., Zhou, S., Pat Bland, M., Lee, A. Y., Hong, K., Walker, C. M., Escobedo, J. A., & Dwarki, V (1997) · Journal of Virology · doi:10.1128/jvi.71.10.7960-7962.1997 · Cited by 122
Pangburn, M. K., Pangburn, K. L. W., Koistinen, V., Meri, S., & Sharma, A. K. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.9.4742 · Cited by 119
Zhang, Y., Chirmule, N., Gao, G.-P., & Wilson, J. (2000) · Journal of Virology · doi:10.1128/jvi.74.17.8003-8010.2000 · Cited by 119
Kiang, A., Hartman, Z. C., Everett, R. S., Serra, D., Jiang, H., Frank, M. M., & Amalfitano, A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.024 · Cited by 92
Complement amplification revisited
Lutz, H. U., & Jelezarova, E. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2005.06.020 · Cited by 87
Jiang, H., Wang, Z., Serra, D., Frank, M. M., & Amalfitano, A. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.08.015 · Cited by 84
Fagiolo, U., Kricek, F., Ruf, C., Peserico, A., Amadori, A., & Cancian, M. (2000) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2000.108913 · Cited by 83
Cottard, V., Valvason, C., Falgarone, G., Lutomski, D., Boissier, M., & Bessis, N. (2004) · Journal of Clinical Immunology · doi:10.1023/b:joci.0000019781.64421.5c · Cited by 77
Identification of the Streptococcal M Protein Binding Site on Membrane Cofactor Protein (CD46)
Giannakis, E., Jokiranta, T. S., Ormsby, R. J., Duthy, T. G., Male, D. A., Christiansen, D., Fischetti, V. A., Bagley, C., Loveland, B. E., & Gordon, D. L. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4585 · Cited by 72
Molina, H., Kinoshita, T., Webster, C. B., & Holers, V. M. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.2.789 · Cited by 66
Self-citationAlitalo, A., Meri, T., Chen, T., Lankinen, H., Cheng, Z.-Z., Jokiranta, T. S., Seppälä, I., Lahdenne, P., Hefty, P. S., Akins, D. R., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.6195 · Cited by 65
Myeloid C3 Determines Induction of Humoral Responses to Peripheral Herpes Simplex Virus Infection
Verschoor, A., Brockman, M. A., Gadjeva, M., Knipe, D. M., & Carroll, M. C. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.10.5363 · Cited by 63
Zhong, L., Li, W., Yang, Z., Qing, K., Tan, M., Hansen, J., Li, Y., Chen, L., Chan, R. J., Bischof, D., et al. (2004) · Human Gene Therapy · doi:10.1089/hum.2004.15.1207 · Cited by 59
Regulation of humoral immune responses by CD21/CD35
Chen, Z., Koralov, S. B., & Kelsoe, G. H. (2000) · Immunological Reviews · doi:10.1034/j.1600-065x.2000.00603.x · Cited by 43
Herpes Simplex Virus Glycoprotein C is a Receptor for Complement Component iC3b
Tal‐Singer, R., Seidel‐Dugan, C., Fries, L. F., Huemer, H. P., Eisenberg, R. J., Cohen, G. H., & Friedman, H. M. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/164.4.750 · Cited by 39
Szomolanyi‐Tsuda, E., Seedhom, M. O., Carroll, M. C., & Garcea, R. L. (2006) · Virology · doi:10.1016/j.virol.2006.04.018 · Cited by 24
Pramoonjago, P., Takeda, J., Kim, Y. U., Inoue, K., & Kinoshita, T. (1993) · International Immunology · doi:10.1093/intimm/5.4.337 · Cited by 23
‘Complementing’ viral infection: mechanisms for evading innate immunity
Lee, S.-H., Jung, J. U., & Means, R. E. (2003) · Trends in Microbiology · doi:10.1016/j.tim.2003.08.004 · Cited by 18
CD11c (leukocyte integrin CR4 alpha subunit).
Cabañas, C., & Sánchez‐Madrid, F. (1999) · PubMed · Cited by 18
Cited by
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Immune Responses to Viral Gene Therapy Vectors
Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
Progress and prospects: immune responses to viral vectors
Nayak, S., & Herzog, R. W. (2010) · Gene Therapy · doi:10.1038/gt.2009.148 · Cited by 634
Metadata
- Authors
- Zaiss, A. K., Cotter, M. J., White, L. R., Clark, S. A., Wong, N. C. W., Holers, V. M., Bartlett, J. S., & Muruve, D. A.
- Affiliations
- Department of Biochemistry and Molecular Biology
- University of Calgary (CA)
- University of Colorado Health (US)
- Abigail Wexner Research Institute (US)
- Corresponding author
- Muruve, Daniel A.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2008-03-15
- Volume
- 82
- Issue
- 6
- Pages
- 2727-2740
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC2259003
- OpenAlex
- W2113089955
- Cited by
- 177
- References
- 75
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 23 · 2023: 26 · 2022: 17 · 2021: 14 · 2020: 12 · 2019: 6 · 2018: 6 · 2017: 2 · 2016: 3 · 2015: 4 · 2014: 3 · 2013: 3 · 2012: 4
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Virology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Heart and Stroke Foundation of Canada
- Fondation pour la Recherche Médicale
- Alberta Heritage Foundation for Medical Research
- Canadian Institutes of Health Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus vectors, complement system, macrophage activation, AAV capsid, complement factor H, C3 deficiency, neutralizing antibodies, humoral immunity, innate immune response, AAV serotypes, NF-κB signaling
- MeSH terms
- Dependovirus, Animals, Antibodies, Viral, Cell Line, Complement System Proteins, Genetic Vectors, Humans, Macrophage Activation, Macrophages, Mice, Inbred C57BL, Gene Expression, Immunoprecipitation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.